Compare MCB & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | CRVS |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2017 | 2016 |
| Metric | MCB | CRVS |
|---|---|---|
| Price | $90.78 | $14.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $98.67 | $30.17 |
| AVG Volume (30 Days) | 102.2K | ★ 757.8K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | 11.64 | ★ 48.04 |
| EPS | ★ 4.40 | N/A |
| Revenue | ★ $11,053,000.00 | N/A |
| Revenue This Year | $37.22 | N/A |
| Revenue Next Year | $14.75 | N/A |
| P/E Ratio | $20.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $64.66 | $5.29 |
| 52 Week High | $102.04 | $26.95 |
| Indicator | MCB | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 51.49 |
| Support Level | $86.40 | $14.24 |
| Resistance Level | $92.99 | $16.66 |
| Average True Range (ATR) | 1.64 | 0.70 |
| MACD | -0.20 | -0.03 |
| Stochastic Oscillator | 6.96 | 56.16 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.